PCSK9 inhibition is still the strongest and safest form of LDL lowering available
10 November 2025
Dr Adrian Cheong Yan Yue
LMCHK (BM BCh University of Oxford), MRCP(UK), FHKAM(Med), FHKCP
Abstract
PCSK9 inhibitor antibodies (e.g., evolocumab, alirocumab) remain among the most potent LDL-lowering therapies available, slashing LDL cholesterol by 50% to 60%. They are primarily reserved for high-risk patients who cannot meet targets with statins or ezetimibe, and they have robust cardiovascular outcomes data proving they prevent heart attacks and strokes.
Dr Adrian Cheong Yan Yue
LMCHK (BM BCh University of Oxford), MRCP(UK), FHKAM(Med), FHKCP
He is a Specialist in Cardiology.